
Tablets
Bi-layered and sustained-release tablets, plus low-RH tablet capability.
Support your product portfolio with specialized manufacturing pathways across Penicillin, Cephalosporins, Steroids and Cytotoxic products.
For a B2B partner, the important question is not simply what can be manufactured—but which specialized manufacturing pathway is aligned to your molecule, dosage form, market and scale.
Unit I · Penicillin

Bi-layered and sustained-release tablets, plus low-RH tablet capability.

Hard gelatin capsule dosage forms within the penicillin unit.

Dry-syrup formulations for penicillin products.

Powders and clavulanic preparations listed under Unit I.
Unit II · Cephalosporins

Cephalosporin tablet formulations.

Cephalosporin products in hard gelatin capsule format.

Dry-syrup dosage forms for cephalosporin products.

Dry-powder injection capability listed under the cephalosporin unit.
Unit III · Steroids

Steroid tablets are explicitly listed under Plant-VIII Unit III.

Steroid ointments are explicitly listed under Plant-VIII Unit III.
Unit IV · Cytotoxic

Disinfectant is listed under the Plant-VIII cytotoxic unit.

Ointments are listed under the Plant-VIII cytotoxic unit.

Topical solution is listed under the Plant-VIII cytotoxic unit.
The manufacturing story starts with your product requirement and maps it to the appropriate specialized production unit.

Plot No. 16, N.H.-58, Vardhman Industrial Estate, Bahadarpur Saini, Roorkee, Haridwar, Uttarakhand.
Capability: Anti-Bacterials and Steroids.

Unit I: Penicillin
Unit II: Cephalosporins
Unit III: Steroids
Unit IV: Cytotoxic

Published approvals include WHO-GMP, GMP certification, Uganda, Cambodia and Malawi regulatory approvals.
For pharma companies, marketers and product owners, this page makes it easy to understand where a product fits within the manufacturing ecosystem before initiating a technical discussion.

Multiple dosage-form pathways across Penicillin and Cephalosporin products help support different product and market requirements.
Dedicated production units provide a structured pathway for Penicillin, Cephalosporins, Steroids and Cytotoxic products.
A specialized manufacturing architecture can help partners plan production around product requirements, volumes and commercial markets.
Published manufacturing approvals and certifications support the facility’s positioning for regulated pharmaceutical markets.
Share your molecule, dosage form, target market and expected volumes. Our team can evaluate the relevant manufacturing and commercialization pathway.
Source basis: Akums current Plant-VIII manufacturing listing and October 2025 Akums brochure. Plant-VIII is published as Anti-Bacterials and Steroids; Unit I is Penicillin, Unit II Cephalosporins, Unit III Steroids (Tablets & Ointments), and Unit IV Cytotoxic (Disinfectant, Ointments & Topical Solution).